Incidence of amyloid-related imaging abnormalities and health resource utilization in patients with Alzheimer disease receiving monoclonal antibody treatments: A real-world evidence study - PubMed
6 hours ago
- #Amyloid-Related Imaging Abnormalities
- #Alzheimer Disease
- #Real-World Evidence
- This real-world evidence study compared patients with Alzheimer disease receiving monoclonal antibody treatments (e.g., aducanumab, lecanemab, donanemab) to a matched group receiving nonmonoclonal treatments (e.g., donepezil, memantine, rivastigmine).
- The monoclonal antibody treatment group had a significantly higher cumulative hazard of amyloid-related imaging abnormalities (ARIA), with a hazard ratio of 4.65, indicating nearly 5 times the risk compared to the nonmonoclonal group.
- Key factors associated with increased ARIA risk included concurrent antithrombotic use, a history of stroke, and hyperlipidemia.
- Despite the higher ARIA risk, the monoclonal antibody group had significantly fewer inpatient visits among patients with at least 180 days of follow-up.
- The study highlights the value of real-world evidence for postapproval drug assessment and informing personalized treatment guidelines based on patient risk factors.